CN

CN

News

Company News Industry News

Company News

FDA Grants IND Approval to YL413, Medilink Therapeutics’ First Dual-Payload ADC

2026-08-01

Medilink Announces Formal Acceptance by NMPA of Marketing Application for Tam-Peli (YL201) for Third-Line and Beyond Treatment of Nasopharyngeal Carcinoma

2026-07-18

MediLink Therapeutics Announces B7-H3 ADC YL201 Met Primary Endpoint in Phase 3 Nasopharyngeal Carcinoma Study

SUZHOU, China – May 29, 2026 – MediLink Therapeutics (Suzhou) Co., Ltd. today announced that tambotatug pelitecan (Tam-Peli, R&D code: YL201), its investigational B7-H3 targeted antibody-drug conjugate (ADC), has achieved positive results in the pre-specified interim analysis of the Phase 3 registrational clinical trial (TAISHAN-301) for recurrent or metastatic nasopharyngeal carcinoma (NPC). The Independent Data Monitoring Committee (IDMC) confirmed that the trial met the endpoint of confirmed objective response rate (cORR) as assessed by Blinded Independent Central Review (BICR), demonstrating a statistically significant improvement compared to chemotherapy. The second co-primary endpoint of overall survival (OS) is not yet mature. This marks the first positive Phase 3 result for any B7-H3 targeted ADC worldwide.

2026-05-30

MEDILINK Successfully Holds National Investigators' Meeting for Tam-Peli Phase III Esophageal Squamous Cell Carcinoma Project in Beijing

1970-01-01Learn more

The special edition of Jiefang Daily praises Medilink’s innovative drug R&D achievements

2026-07-15Learn more

Shining at ASCO 2026 | MediLink Therapeutics Presents Multiple Clinical Studies, Showcasing ADC Innovation

The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting will take place May 29 – June 2 in Chicago, IL. As the world’s largest, most influential, and authoritative oncology conference, ASCO drives global progress in cancer research, clinical development, and patient care.

2026-05-20Learn more

MediLink Therapeutics Presents Two Innovative ADC Programs at AACR 2026

MediLink Therapeutics, a clinical-stage biotechnology company focused on next-generation antibody-drug conjugates (ADCs), is pleased to share two cutting-edge research posters at the AACR 2026 Annual Meeting (April 17–22, San Diego, USA).

2026-04-23Learn more

MediLink Has Signed an Additional Exclusive Licensing Agreement with Roche

Suzhou, China, January 9th, 2026 – MediLink Therapeutics (“MediLink”) today announced that it has entered into a new collaboration and exclusive licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the development and commercialization of YL201, an investigational novel antibody-drug conjugate (ADC) asset targeting B7H3 across numerous solid tumor types.

2026-01-09Learn more

MediLink Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of YL217

July 2, 2025 – MediLink Therapeutics, a clinical-stage biotechnology company, today announced that the first patient has been enrolled and dosed in China in the Global Phase I clinical trial of YL217. YL217 is a CDH17-targeting antibody-drug conjugate (ADC) based on MediLink’s proprietary TMALIN® technology platform.

2025-07-03Learn more
1 2 3 4 5 6 7